Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 1.00 |
| ▸ | THRA | P10827 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | PCNA | P12004 | 2/20 | 0.77 |
| ▸ | PPARG | P37231 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | GABRP | O00591 | 1/20 | 0.77 |
| ▸ | GABRD | O14764 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | F2 | P00734 | 1/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.77 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.77 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.77 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9619560 | 1.00 | THRB (1.00) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL9170207 | 1.00 | THRB (1.00) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL6827511 | 0.91 | THRB (0.84) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL7277669 | 0.90 | THRB (0.84) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL7277661 | 0.90 | THRB (0.84) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL5549652 | 0.88 | THRB (1.00) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL3219487 | 0.88 | THRB (1.00) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL3219497 | 0.88 | THRB (1.00) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL7276775 | 0.87 | THRB (0.77) | THRBTHRAMEN1KMT2ALMNA | |
| SCHEMBL7276780 | 0.87 | THRB (0.77) | THRBTHRAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0163122-B1 | METHOD FOR THE DETERMINATION OF FREE SUBSTANCES IN BIOLOGICAL FLUIDS | Henning Berlin GmbH Chemie- und Pharmawerk (DE) | 1992-03-04 | — | — | EP | claimed |
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-01 | — | — | US | disclosed |
| EP-0873361-B1 | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand | UNIV CALIFORNIA (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7122579-B2 | Eye treatments using synthetic thyroid hormone compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030175849-A1 | Eye treatments using synthetic thyroid hormone compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-18 | — | — | US | disclosed |
| US-6555582-B1 | Topically applying a synthetic thyroid hormone to inhibit hyaluronic acid secretion to treat elevated intraocular pressure and glaucoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-29 | — | — | US | disclosed |
| EP-0873361-A4 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | UNIV CALIFORNIA (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1003530-A4 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | UNIV CALIFORNIA (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6236946-B1 | Nuclear receptor ligands and ligand binding domains | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-05-22 | — | — | US | disclosed |
| EP-1034184-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | The Regents of the University of California (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1003530-A1 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | The Regents of the University of California (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6054485-A | FOR TREATMENT OF GLAUCOMA | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999026966-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0873361-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998007435-A9 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998007435-A1 | EYE TREATMENTS USING SYNTHETIC THYROID HORMONE COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997021993-A2 | NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0466909-B1 | THYROID HORMONE FOR CARDIAC TREATMENT | BRITISH TECH GROUP USA (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027215-A1 | Nuclear receptor ligands and ligand binding domains | TSHR, NR5A2, THRA | THRB 6/4885THRA 3/4885MEN1 3633/4885 |
| US-20030175849-A1 | Eye treatments using synthetic thyroid hormone compositions | ADAMTS5, TRHDE, ADAMTS1 | THRB 17/4885THRA 12/4885MEN1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.